These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 35155258)
21. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547 [TBL] [Abstract][Full Text] [Related]
23. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
24. [Research Advances in CIMAvax-EGF for Non-small-cell Lung Cancer]. Zhang JY; Zhu L; Yang HK; Chen F Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Jun; 40(3):411-414. PubMed ID: 29978802 [TBL] [Abstract][Full Text] [Related]
25. Biomodulina T May Restore Immunity in Older Adults. Suárez-Formigo GM; Saavedra-Hernández D MEDICC Rev; 2020 Jul; 22(3):54-56. PubMed ID: 32812900 [TBL] [Abstract][Full Text] [Related]
26. Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF. Fernández Lorente A; Acosta Brooks S; Neninger Vinageras E; Barroso Alvarez Mdel C; Wilkinson Brito B; Troche Concepción M; Martínez Pérez LB; Viada González CE; Crespo Diaz T; Casacó Parada AR World J Surg Oncol; 2013 Oct; 11():275. PubMed ID: 24127898 [TBL] [Abstract][Full Text] [Related]
27. Repeated dose intramuscular injection of the CIMAvax-EGF vaccine in Sprague Dawley rats induces local and systemic toxicity. Mancebo A; Casacó A; González B; Ledón N; Sorlozabal J; León A; Gómez D; González Y; Bada AM; González C; Arteaga ME; Ramírez H; Fuentes D Vaccine; 2012 May; 30(22):3329-38. PubMed ID: 22433960 [TBL] [Abstract][Full Text] [Related]
28. [Expression of PD-1 and PD-L1 in the peripheral blood of advanced non-small-cell lung cancer patients and its implications]. Xing YF; Pan X; Qian B; Shi MH Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):111-114. PubMed ID: 30669748 [No Abstract] [Full Text] [Related]
29. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer. Hoffner B; Leighl NB; Davies M Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962 [TBL] [Abstract][Full Text] [Related]
30. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Schvartsman G; Peng SA; Bis G; Lee JJ; Benveniste MFK; Zhang J; Roarty EB; Lacerda L; Swisher S; Heymach JV; Fossella FV; William WN Lung Cancer; 2017 Oct; 112():90-95. PubMed ID: 29191606 [TBL] [Abstract][Full Text] [Related]
31. Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor. Inomata M; Kado T; Okazawa S; Imanishi S; Taka C; Kambara K; Hirai T; Tanaka H; Tokui K; Hayashi K; Miwa T; Hayashi R; Matsui S; Tobe K Anticancer Res; 2019 Dec; 39(12):6887-6893. PubMed ID: 31810958 [TBL] [Abstract][Full Text] [Related]
32. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405 [No Abstract] [Full Text] [Related]
33. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866 [TBL] [Abstract][Full Text] [Related]
34. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856 [TBL] [Abstract][Full Text] [Related]
35. Evodiamine suppresses non-small cell lung cancer by elevating CD8 Jiang ZB; Huang JM; Xie YJ; Zhang YZ; Chang C; Lai HL; Wang W; Yao XJ; Fan XX; Wu QB; Xie C; Wang MF; Leung EL J Exp Clin Cancer Res; 2020 Nov; 39(1):249. PubMed ID: 33208183 [TBL] [Abstract][Full Text] [Related]
36. Induction of Peripheral Effector CD8 T-cell Proliferation by Combination of Paclitaxel, Carboplatin, and Bevacizumab in Non-small Cell Lung Cancer Patients. de Goeje PL; Poncin M; Bezemer K; Kaijen-Lambers MEH; Groen HJM; Smit EF; Dingemans AC; Kunert A; Hendriks RW; Aerts JGJV Clin Cancer Res; 2019 Apr; 25(7):2219-2227. PubMed ID: 30642911 [TBL] [Abstract][Full Text] [Related]
37. Expression of PD1 and BTLA on the CD8 Bao Y; Mo JF; Wu JY; Cao CX Chin Med Sci J; 2019 Nov; 34(4):248-255. PubMed ID: 33906710 [No Abstract] [Full Text] [Related]
38. History of the discovery and development of Biomodulina T (InmunyVital®), a useful immunomodulator with a broad range of clinical applications. Rodriguez Martin RR; Gonzalez Gonzalez O; Rodriguez Gonzalez C; Rodriguez Gonzalez RR Int Immunopharmacol; 2023 Jun; 119():110167. PubMed ID: 37086680 [TBL] [Abstract][Full Text] [Related]
39. Variations in DNA methylation of interferon gamma and programmed death 1 in allograft rejection after kidney transplantation. Boer K; de Wit LE; Peters FS; Hesselink DA; Hofland LJ; Betjes MG; Looman CW; Baan CC Clin Epigenetics; 2016; 8():116. PubMed ID: 27891189 [TBL] [Abstract][Full Text] [Related]